ERBB2 and breast carcinoma: This is illustrated by the recent FDA approval of trastuzumab deruxtecan for the treatment of unresectable or metastatic HER2+ breast cancer and later in 2021 for the treatment of HER2+ locally advanced or metastatic gastric cancer.